United Therapeutics Corporation or Taro Pharmaceutical Industries Ltd.: Who Manages SG&A Costs Better?

Pharma Giants' SG&A Strategies: A Decade in Review

__timestampTaro Pharmaceutical Industries Ltd.United Therapeutics Corporation
Wednesday, January 1, 201491733000381287000
Thursday, January 1, 201587644000452612000
Friday, January 1, 201692365000316800000
Sunday, January 1, 201785656000330100000
Monday, January 1, 201888196000265800000
Tuesday, January 1, 201989971000336200000
Wednesday, January 1, 202093413000423900000
Friday, January 1, 202191355000467000000
Saturday, January 1, 2022113676000487000000
Sunday, January 1, 2023198366000477100000
Monday, January 1, 2024218935000
Loading chart...

Unleashing the power of data

SG&A Cost Management: A Tale of Two Pharmaceutical Giants

In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. United Therapeutics Corporation and Taro Pharmaceutical Industries Ltd. have taken different paths in this regard over the past decade. From 2014 to 2023, United Therapeutics consistently reported higher SG&A expenses, peaking at nearly 487% more than Taro's in 2022. However, Taro's SG&A costs surged by 92% from 2022 to 2023, indicating a strategic shift or increased operational costs. Despite United Therapeutics' higher expenses, their consistent growth suggests a robust strategy in leveraging these costs for expansion. Meanwhile, Taro's recent spike raises questions about future financial strategies. As we look to 2024, with data still emerging, the pharmaceutical industry will be keenly observing how these giants balance cost management with growth ambitions.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025